GTBP · GT Biopharma, Inc. · Exempt Offerings
$3.72
-0.12 (-3.13%)
At close · Nov 13
Return incl. dividend (before tax)
Q2 2021 earnings call transcript
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, raised substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$6.71M
Shares
1.80M
Volume · Nov 13
66.92K
Avg daily vol (48 sessions)
89.87K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2026-09-29 | New | Biotechnology | $38,958,054 | $7,750,000 | 06b |
| 2025-05-28 | New | Biotechnology | $20,000,000 | $0 | 06b |
| 2025-05-27 | New | Biotechnology | $5,950,000 | $5,950,000 | 06b |
| 2025-03-07 | New | Biotechnology | $1,280,358 | $1,280,358 | 06b |
| 2020-07-23 | Amendment | Biotechnology | Indefinite | $5,607,000 | 06b |
| 2020-06-12 | New | Biotechnology | Indefinite | $2,417,000 | 06b |
Showing 1–6 of 6 filings
Key facts
CIK
109657
CUSIP
36254L407
13F (30d)
26 filings
18 filers
Visit website
Investor relations